Cardiovascular characteristics in subjects with increasing levels of abnormal glucose regulation: The strong heart study

Diabetes Care

Volumn 36, Issue 4, 2013, Pages 992-997

  Capaldo, Brunella ^a   Di Bonito, Procolo ^b   Iaccarino, Michele ^a   Roman, Mary J ^c   Lee, Elisa T ^d   Devereux, Richard B ^c   Riccardi, Gabriele ^a   Howard, Barbara V ^e   De Simone, Giovanni ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Pozzuoli Hospital   (Italy)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e MEDSTAR HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; INSULIN; LIPID; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PROBABILITY; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; ECHOCARDIOGRAPHY; FASTING; FEMALE; FIBRINOGEN; GLUCOSE; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; ODDS RATIO; TRIGLYCERIDES;

EID: 84875420355     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1501     Document Type: Article

References (40)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038
2. Stamler J, VaccaroO, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality formen screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444
3. DECODE Study Group; the European Diabetes Epidemiology Study Group. Glucose tolerance and cardiovascular mortality: comparisons of fasting and 2-h diagnostic criteria. Arch Intern Med 2001;161:397-405
4. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011;108(Suppl.):3B-24B
5. Faeh D, William J, Yerly P, Paccaud F, Bovet P. Diabetes and pre-diabetes are associated with cardiovascular risk factors and carotid/femoral intima-media thickness independently of markers of insulin resistance and adiposity. Cardiovasc Diabetol 2007;6:32-42
6. Barr ELM, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individualswith diabetesmellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:151-157
7. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010;55:1310-1317
8. Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 1999; 16:212-218
9. Pankow JS, Kwan DK, Duncan BB, et al. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007;30:325-331
10. de Simone G, Devereux RB, Palmieri V, et al. Relation of insulin resistance to markers of preclinical cardiovascular disease: the Strong Heart Study. Nutr Metab Cardiovasc Dis 2003;13:140-147
11. Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003; 107:448-454
12. Velagaleti RS, Gona P, Chuang ML, et al. Relations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: the Framingham Heart Study. Circ Cardiovasc Imaging 2010;3: 257-263
13. Celentano A, Vaccaro O, Tammaro P, et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol 1995;76:1173-1176
14. Ilercil A, Devereux RB, Roman MJ, et al. Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study. Am Heart J 2001;141:992-998
15. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 2000;101:2271-2276
16. Howard BV, Lee ET, Cowan LD, et al. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 1999;99:2389-2395
17. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem1999; 45:2136-2141
18. Palmieri V, Celentano A, Roman MJ, et al. Fibrinogen and preclinical echocardiographic target organ damage: the Strong Heart Study. Hypertension 2001;38: 1068-1074
19. de Simone G, Kizer JR, Chinali M, et al.; Strong Heart Study Investigators. Normalization for body size and populationattributable risk of left ventricular hypertrophy: the Strong Heart Study.Am J Hypertens 2005;18:191-196
20. de Simone G, Devereux RB, Chinali M, et al. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study. Nutr Metab Cardiovasc Dis 2009; 19:98-104
21. de Simone G, Devereux RB, Ganau A, et al. Estimation of left ventricular chamber and stroke volume by limited M-mode echocardiography and validation by twodimensional and Doppler echocardiography. Am J Cardiol 1996;78:801-807
22. Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 2002; 105:1928-1933
23. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999;48: 2197-2203
24. De Marco M, de Simone G, Roman MJ, et al. Cardiac geometry and function in diabetic or prediabetic adolescents and young adults: the Strong Heart Study. Diabetes Care 2011;34:2300-2305
25. De Simone G, Devereux RB, Chinali M, et al. Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study. J Hypertens 2011; 29:1431-1438
26. Kuch B, Muscholl M, Luchner A, et al. Gender specific differences in left ventricular adaptation to obesity and hypertension. J Hum Hypertens 1998;12:685-691
27. Schillaci G, Pirro M, Pucci G, et al. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension 2006;47:881-886
28. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881-885
29. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687
30. Qiao Q, Pyörälä K, Pyörälä M, et al. Twohour glucose is a better risk predictor for incident coronary heart disease and cardiovascularmortality than fasting glucose. Eur Heart J 2002;23:1267-1275
31. Ning F, Tuomilehto J, Pyörälä K, Onat A, Söderberg S, Qiao Q; DECODE Study Group. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 2010;33: 2211-2216
32. Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002;155:65-71
33. Kawamoto R, Tabara Y, Kohara K, et al. Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population. Cardiovasc Diabetol 2011;10:51-59
34. SabanayagamC, Shankar A, Lim SC, Lee J, Tai ES, Wong TY. Serum C-reactive protein level and prediabetes in two Asian populations. Diabetologia 2011;54:767-775
35. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis.Nat Rev Cardiol 2009;6: 399-6409
36. Arnett DK, McClelland RL, Bank A, et al. Biomarkers of inflammation and hemostasis associated with left ventricularmass: The Multiethnic Study of Atherosclerosis (MESA). Int J Mol Epidemiol Genet 2011; 2:391-400
37. González A, Ravassa S, Beaumont J, López B, Díez J. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol 2011;58:1833-1843
38. Cioffi G, Tarantini L, Frizzi R, et al. Chronic kidney disease elicits excessive increase in left ventricular mass growth in patients at increased risk for cardiovascular events. J Hypertens 2011;29:565-573
39. Cioffi G, Russo TE, Stefenelli C, et al. Severe obstructive sleep apnea elicits concentric left ventricular geometry. J Hypertens 2010;28:1074-1082
40. Roes SD, Dehnavi RA, Westenberg JJ, et al. Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome. J Cardiovasc Magn Reson 2011;13:65-72